Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis
Comprehensive genomic profiling (CGP) allows for the detection of driver alterations at high resolution, but the limited number of approved targeted therapies and their high costs have contributed to its limited clinical utilization. We retrospectively compared data of 946 women with ovarian cancer...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/1/218 |
| _version_ | 1797626144590135296 |
|---|---|
| author | Shira Peleg Hasson Dov Hershkovitz Lyri Adar Miriam Brezis Eliya Shachar Rona Aks Lee Galmor Yuval Raviv Shira Ben Neriah Ofer Merimsky Edmond Sabo Ido Wolf Tamar Safra |
| author_facet | Shira Peleg Hasson Dov Hershkovitz Lyri Adar Miriam Brezis Eliya Shachar Rona Aks Lee Galmor Yuval Raviv Shira Ben Neriah Ofer Merimsky Edmond Sabo Ido Wolf Tamar Safra |
| author_sort | Shira Peleg Hasson |
| collection | DOAJ |
| description | Comprehensive genomic profiling (CGP) allows for the detection of driver alterations at high resolution, but the limited number of approved targeted therapies and their high costs have contributed to its limited clinical utilization. We retrospectively compared data of 946 women with ovarian cancer (11.4% were referred to CGP, and 88.6% served as control) to examine whether CGP provides a prognosis benefit. Patient baseline parameters were similar between the groups. Cox regression analysis adjusted for age, disease stage at diagnosis, and recurrence status showed statistically significantly longer median overall survival (mOS) in the CGP group versus the control (73.4 versus 54.5 months, <i>p</i> < 0.001). Fifty-four patients (52.9%) had actionable mutations with potential treatments; twenty-six (48.2%) were treated with matched targeted therapy, showing a trend for longer mOS than the eighty-six women in the CGP group who were not given a suggested treatment (105.5 versus 63.6 months, <i>p</i> = 0.066). None of the genomic alterations predicted metastasis location. CCNE1 amplification and KRAS mutations were associated with shorter mOS. Patients with tumor mutation burden ≥4 mutations/megabase had longer mOS. High loss of heterozygosity was associated with longer mOS (99.0 versus 48.2 months, <i>p</i> = 0.004). CGP testing may provide both prognostic and predictive insights for treatment of patients with ovarian cancer. Prospective studies of larger cohorts are warranted. |
| first_indexed | 2024-03-11T10:06:19Z |
| format | Article |
| id | doaj.art-dbb1ff823159438d8277e33524a58f13 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T10:06:19Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-dbb1ff823159438d8277e33524a58f132023-11-16T15:03:12ZengMDPI AGCancers2072-66942022-12-0115121810.3390/cancers15010218Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective AnalysisShira Peleg Hasson0Dov Hershkovitz1Lyri Adar2Miriam Brezis3Eliya Shachar4Rona Aks5Lee Galmor6Yuval Raviv7Shira Ben Neriah8Ofer Merimsky9Edmond Sabo10Ido Wolf11Tamar Safra12Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelPathology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelSackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelDepartment of Pathology, Carmel Medical Center, Haifa 3436212, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelOncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, IsraelComprehensive genomic profiling (CGP) allows for the detection of driver alterations at high resolution, but the limited number of approved targeted therapies and their high costs have contributed to its limited clinical utilization. We retrospectively compared data of 946 women with ovarian cancer (11.4% were referred to CGP, and 88.6% served as control) to examine whether CGP provides a prognosis benefit. Patient baseline parameters were similar between the groups. Cox regression analysis adjusted for age, disease stage at diagnosis, and recurrence status showed statistically significantly longer median overall survival (mOS) in the CGP group versus the control (73.4 versus 54.5 months, <i>p</i> < 0.001). Fifty-four patients (52.9%) had actionable mutations with potential treatments; twenty-six (48.2%) were treated with matched targeted therapy, showing a trend for longer mOS than the eighty-six women in the CGP group who were not given a suggested treatment (105.5 versus 63.6 months, <i>p</i> = 0.066). None of the genomic alterations predicted metastasis location. CCNE1 amplification and KRAS mutations were associated with shorter mOS. Patients with tumor mutation burden ≥4 mutations/megabase had longer mOS. High loss of heterozygosity was associated with longer mOS (99.0 versus 48.2 months, <i>p</i> = 0.004). CGP testing may provide both prognostic and predictive insights for treatment of patients with ovarian cancer. Prospective studies of larger cohorts are warranted.https://www.mdpi.com/2072-6694/15/1/218comprehensive genomic profilinggenomic alterationsmatched therapyovarian canceroverall survival |
| spellingShingle | Shira Peleg Hasson Dov Hershkovitz Lyri Adar Miriam Brezis Eliya Shachar Rona Aks Lee Galmor Yuval Raviv Shira Ben Neriah Ofer Merimsky Edmond Sabo Ido Wolf Tamar Safra Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis Cancers comprehensive genomic profiling genomic alterations matched therapy ovarian cancer overall survival |
| title | Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis |
| title_full | Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis |
| title_fullStr | Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis |
| title_full_unstemmed | Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis |
| title_short | Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis |
| title_sort | implementation of comprehensive genomic profiling in ovarian cancer patients a retrospective analysis |
| topic | comprehensive genomic profiling genomic alterations matched therapy ovarian cancer overall survival |
| url | https://www.mdpi.com/2072-6694/15/1/218 |
| work_keys_str_mv | AT shirapeleghasson implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT dovhershkovitz implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT lyriadar implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT miriambrezis implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT eliyashachar implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT ronaaks implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT leegalmor implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT yuvalraviv implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT shirabenneriah implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT ofermerimsky implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT edmondsabo implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT idowolf implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis AT tamarsafra implementationofcomprehensivegenomicprofilinginovariancancerpatientsaretrospectiveanalysis |